

Bio Farma Daftarkan Pentabio ke WHO



PT. Bio Farma (Persero) tengah mendaftarkan produk vaksin Pentabio yang merupakan kombinasi jerap Difteri, Tetanus, Pertusiss, hepatitis B rekombinan, haemophilus Influenza tipe B ke badan kesehatan dunia (WHO). Head Corporate Communication Departement Bio Farma N. Nurlela Arief mengatakan Pentabio yang sejauh ini sudah disebarakan di beberapa provinsi Indonesia diharapkan akan semakin berkontribusi setelah vaksin ini teregister di badan kesehatan dunia (WHO). "Hingga kini Bio Farma telah memasarkan ke 127 negara dengan penjualan 12 jenis vaksin yang bisa dipasarkan di tingkat internasional, " tuturnya disela-sela *Workshop School of Vaccine for Journalist* di Jakarta, Selasa (19/8). Pentabio digunakan untuk pencegahan terhadap difteri, tetanus, pertussis (batuk rejan), hepatitis B, dan infeksi heamophilus influenza tipe B (HiB) secara simultan. Direktur utama Bio Farma, Iskandar mengatakan pengembangan produk terus dilakukan manajemen untuk meningkatkan kinerja perseroan. Selain mengembangkan inovasi produk, peningkatan kinerja dengan menguasai *platform* teknologi juga dilakukan. Menurutnya, saat ini tingkat komponen dalam negeri produk Bio Farma telah mencapai 70 persen dengan menguasai komponen utama dalam pembuatan vaksin. "Inovasi menjadi kekuatan utama, pembuatan vaksin bukanlah hal mudah dan membutuhkan energy yang tinggi. Saat ini kami sedang mengembangkan teknologi rekombinan," tuturnya. Dia mengatakan saat ini mayoritas penjualam perseroan didukung dari ekspor yang mencapai 65 persen dan tidak menggantungkan penjualannya dengan pemerintah. Pada tahun lalu, perluasan pasar baru pada 14 negara-negara Amerika Latin menjadi factor utama terdongkraknya kinerja. **PENJUALAN TUMBUH** Menurut laporan keuangan Bio Farma, total penjualan pada 2013 mebcapai 1,88 triliun atau tumbuh 28, 94 persen dibandingkan dengan penjualan tahun sebelumnya. Tidak hanya itu, capaian laba bersih pada 2013 tumbuh subur sebesar 48,35 persen atau sebesar Rp572,47 miliar terhadap 2012. "Saat ini kami juga mempunyai bibit yang akan mampu memenuhi kebutuhan produksi selama 100 tahun. Kalau kami mengandalkan impor tentunya lebih mudah, tetapi kami tidak merdeka." Sementara itu, Direktur Jendral Bina Kefarmasian dan Alat Kesehatan Kemenkes RI Maura Linda Sitanggang menuturkan pemerintah terus mendukung Bio Farma dalam mengembangkan produk vaksinya. "Kami persilahkan siapa saja untuk mengembangkan dan berinovasi, tetapi perlu diingat akhir dari penelitian yang ada diharapkan bisa dipasarkan. Jangan hanya berkutat di laboratorium, dan kami mendorong industry untuk lebih cepat," katanya. Diia menambahkan keterbatasan anggaran diharapkan tidak menjadi alasan peneliti dalam menghasilkan sesuatu. Menurutnya pemerintah kedepan akan lebih memprioritaskan anggaran penelitian untuk menyumbangkan inovasi dan produknya. "Kita memang harus lebih kuat tetapi juga harus diakui tidak bisa bekerja sendiri. Kedepannya guna menuju kemandirian farmasi

yang lebih kuat, anggaran penelitian ditingkatkan," tambahnya. **Sumber: Bisnis Indonesia, 20 Agustus 2014**

PT. Bio Farma (Company) is registering a vaccine product of Pentabio which is the combination of Diphtheria, Tetanus, Pertussis, recombinant hepatitis B, Haemophilus Influenza type B to the World Health Organization (WHO). The Head of Corporate Communications of the Department of Bio Farma N. Nurlela Arief said the Pentabio that so far has been deployed in several provinces in Indonesia is expected to further contribute after the vaccine was registered in the World Health Organization (WHO). "Until now, Bio Farma has marketed to 127 countries with sales of 12 types of vaccines that can be marketed on an international level," he said on the the Workshop School of Vaccine for Journalist in Jakarta, Tuesday (19/8). Pentabio is used for the prevention of diphtheria, tetanus, pertussis (whooping cough), hepatitis B, and influenza infection haemophilus type B (Hib) simultaneously. The Managing director of Bio Farma, Iskandar said the development of product must be done continuously by the management to improve the company's performance. In addition to developing innovative products, the improved performance by mastering the technology platform was also performed. According to him, the current level of domestic component of Bio Farma product has reached 70 percent by mastering major component in the manufacture of vaccines. "Innovation is becoming a major force, the manufacturing of vaccines is not easy and requires the great energy. Currently we are developing recombinant technology," he said. He said the sale majority of the company is supported by the exports which reached 65 per cent and not hang its sale with government. Last year, the expansion of new markets in 14 countries of Latin America became a major factor of the increase of performance. **THE SALES GROW** According to the financial statements of Bio Farma, total sales in 2013 reach 1.88 trillion, or growing 28 to 94 percent compared to the previous year's sales. Not only that, the achievement of net income in 2013 grew well of 48.35 percent or Rp572,47 billion against 2012. "We also have seeds that will be able to meet the production needs for 100 years. If we rely on imports, it is certainly easier, but we are not free." Meanwhile, the Directorate General of Pharmaceutical and Medical Devices of Ministry of Health of Indonesia Maura Linda Sitanggang said the government still continues to support the Bio Farma in developing its vaccine products. "We invite anyone to develop and inivate, but keep in mind in the end of the existing research there is expected to be marketed. Do not just dwell in the laboratory, and we encourage industry to more quickly," he said. He adds the budget constraints are expected not to be the researchers reason to produce something. He said the government would prioritize the research budget to donate and product innovation. "We have to be strong but also to be recognized since we can not work alone. In the future, to leading pharmaceutical stronger Self-Reliance, the research budget is increased," he added. **Source: Bisnis Indonesia, August 20, 2014**